Basic Seroquel Information

• INN (International Nonproprietary Name): Quetiapine.
• Brand Names Available In Australia: Seroquel and Seroquel XR are listed among international brand names for quetiapine; specific Australian-only brand variants are not specified in the supplied data.
• ATC Code: N05AH04 (Atypical second-generation antipsychotics).
• Forms & Dosages: Immediate-release tablets 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 300 mg and 400 mg; Extended-release (XR) tablets 50 mg, 150 mg, 200 mg, 300 mg and 400 mg; no parenteral or liquid forms specified.
• Manufacturers In Australia: AstraZeneca (original developer) and multiple generics suppliers listed internationally include Teva, Sandoz, Torrent, Sun Pharma, Aurobindo, Mylan, Dr. Reddy’s and Accord Healthcare; specific Australian manufacturers are not specified in the supplied data.
• Registration Status In Australia: Not specified in the supplied data.
• OTC / Rx Classification: Prescription (Rx) only in the supplied data; not available over the counter according to the dataset.

Latest Research Highlights

Worried about what recent studies say about effectiveness and safety?

Recent literature since 2022 continues to support quetiapine for acute schizophrenia and bipolar mania, and as adjunctive therapy in major depressive disorder in short-term trials according to the summary in the supplied dataset.

Meta-analyses across 2022–2025 emphasise consistent sedation and metabolic signals such as weight gain, elevated lipids and glycaemic change as the main safety trade-offs as reported in contemporary reviews.

Rare but serious events noted in the broader literature and pharmacovigilance summaries include orthostatic hypotension and neutropenia as safety concerns.

Australian pharmacovigilance reports mirror global patterns with sedation, hypotension, metabolic changes and falls in older adults among the most reported adverse events as highlighted by regulators internationally.

Practice implications repeatedly recommended are baseline physical screening and regular monitoring of weight, lipids and glycaemic markers before and after starting treatment.

Note that long-term real-world comparative effectiveness in Australian community settings remains limited, and registry-based studies are ongoing according to recent commentary.

Common search queries patients use include Seroquel, quetiapine and metabolic risk when looking for evidence and side-effect profiles.

Clinical Effectiveness In Australia

Are clinicians in Australia seeing the same benefits that trials report?

Clinical outcomes observed in Australian practice align broadly with trial data showing effectiveness for psychosis control and acute mania, and modest benefit as adjunctive therapy in depression when antidepressant response is inadequate according to the supplied dataset summary.

TGA approvals follow international indications in practice even though specific TGA registration details were not provided in the supplied data.

Quetiapine appears on many hospital formularies and is commonly prescribed in public and private psychiatric services internationally and in routine formularies per the dataset.

Real-world effectiveness is influenced by adherence with sedation and weight gain being important drivers of non-adherence.

Formulation choice matters; extended-release (Seroquel XR) often improves single-night dosing and tolerability for patients experiencing daytime sedation on immediate-release tablets.

• Baseline monitoring checklist: weight/BMI, fasting lipids, HbA1c or fasting glucose, blood pressure and pulse, liver function tests and medication reconciliation.
• Follow-up monitoring checklist: review at 1 month, 3 months and 6 months for metabolic markers, and sooner if sedation or orthostatic symptoms occur.

Shared-care workflow between psychiatrists, GPs and pharmacists should include clear documentation of authority requirements for PBS prescribing, regular metabolic checks, and telehealth-enabled follow-up where access is limited.

Typical dose ranges in the supplied dataset: schizophrenia 300–400 mg/day target, bipolar mania titrated to about 400 mg by Day 4, bipolar depression up-titration to 300 mg at bedtime, and adjunct in MDD commonly starting at 50 mg XR at bedtime up to 150–300 mg.

Indications And Expanded Uses

Wondering which conditions quetiapine is approved for and when off‑label use is seen?

TGA-aligned indications commonly prescribed include schizophrenia, bipolar mania, bipolar depression and adjunctive treatment for major depressive disorder as reflected in international approvals and dataset standard dosing.

Standard dosing per the supplied data is 300–400 mg/day target for schizophrenia, rapid titration to about 400 mg by Day 4 for mania, and up-titration to 300 mg at bedtime for bipolar depression.

Off‑label Australian practices reported internationally and in clinical use include low-dose quetiapine for severe insomnia, behavioural agitation and adjunct treatment for anxiety, but these uses attract controversy due to safety concerns and limited evidence.

Particular caution applies to people with dementia because of the documented increased mortality risk in elderly patients with dementia-related psychosis.

1. TGA-Approved Uses: Schizophrenia, Bipolar Mania, Bipolar Depression, Adjunct In Major Depressive Disorder (per dataset standard dosing).
2. Common Off-Label Uses: Short-term low-dose insomnia management, behavioural agitation and anxiety adjuncts — document rationale and obtain informed consent.

When prescribing off‑label, clinicians should document the clinical rationale, obtain informed consent and arrange closer monitoring for metabolic, cardiovascular and fall risks per the supplied dataset guidance.

Composition And Brand Landscape

Which brand should patients expect to see on the shelf at the pharmacy?

The active ingredient is quetiapine (INN), commonly presented as quetiapine fumarate in formulations though the supplied dataset lists the INN as quetiapine.

Market brands noted in the dataset include Seroquel and Seroquel XR by AstraZeneca plus multiple generics such as Teva, Sandoz, Torrent, Sun Pharma, Aurobindo, Mylan and Dr. Reddy’s.

No parenteral or liquid forms are listed in the dataset and distribution to hospital formularies and community pharmacies is standard with pricing and PBS listing determining out-of-pocket costs.

Contraindications And Special Precautions

Who should be assessed more carefully before starting quetiapine?

Absolute contraindication in the supplied data is known hypersensitivity to quetiapine or any component of the formulation.

High‑risk populations flagged in the dataset include older adults with dementia (increased mortality), people with cardiovascular disease, significant hepatic impairment, diabetes or metabolic syndrome, seizure disorders, history of leukopenia/neutropenia and patients with a history of cataracts.

Culturally attuned care requires screening for increased cardiometabolic risk among Aboriginal and Torres Strait Islander peoples and involving local Aboriginal Health Services where appropriate.

Practical patient advice includes not driving or operating heavy machinery until tolerance is known, avoiding alcohol and other sedatives, and implementing fall‑prevention strategies for older adults.

Dosage Guidelines

What starting doses and titration schedules are used for each condition?

Standard regimens from the supplied dataset for schizophrenia in adults start at 25 mg twice daily with a typical target of 300–400 mg/day in two to three divided doses and a maximum of 800 mg/day.

Bipolar mania regimens in the supplied data typically start at 50 mg twice daily and increase to around 400 mg by Day 4 with a maximum of 800 mg/day.

Bipolar depression dosing in adults usually begins at 50 mg once daily with titration to 300 mg at bedtime and a 300 mg maximum for that indication.

Adjunctive dosing in major depressive disorder commonly starts at 50 mg XR at bedtime and can be increased to 150–300 mg XR at bedtime with a 300 mg daily maximum noted in the dataset.

Dose adjustments recommended in the dataset include lower starting doses and slow titration in the elderly, conservative titration in adolescents (approved ages noted), and lower initial dosing in hepatic impairment due to hepatic metabolism.

Practical tips for prescribers include documenting the choice of XR versus immediate-release, counselling patients not to crush XR tablets, and aligning titration with PBS authority requirements where applicable.

Interactions Overview

Which medicines and substances commonly cause problems with quetiapine?

Quetiapine is mainly metabolised by the liver, making it susceptible to interactions with strong enzyme inducers and inhibitors that alter plasma levels as described in the dataset.

Additive sedation with alcohol, benzodiazepines, opioids and other CNS depressants is clinically relevant and patients should be counselled to avoid alcohol and monitor concomitant sedating medicines.

Concomitant use with antihypertensives can increase the risk of orthostatic hypotension and close monitoring of blood pressure and symptoms is advised.

Pharmacists reviewing scripts should prioritise checking for polypharmacy with antidepressants, mood stabilisers and other antipsychotics and counsel patients on CNS depression and metabolic monitoring.

Cultural Perceptions And Patient Habits

What do Australian patients say about using quetiapine?

Many patients report quetiapine is effective, but common concerns expressed online and in forums relate to sedation and weight gain that affect daily functioning, work and study.

Rural and remote patients commonly rely on GPs and telehealth for psychiatry prescriptions due to fewer on‑site mental health specialists and longer waits for specialist review.

Community pharmacies, including remote outlets, are trusted local sources for counselling and continuity of supply in regional Australia.

Price sensitivity and PBS subsidy reliance often drive patient preference for generic formulations over branded Seroquel, with shoppers comparing prices across chains such as Chemist Warehouse and Priceline.

For Aboriginal and Torres Strait Islander communities, culturally safe communication and involvement of community health workers increases trust and adherence according to best-practice recommendations in clinical services.

Availability And Pricing Patterns

How easy is it for patients across Australia to get quetiapine and how much will it typically cost?

Seroquel and generic quetiapine are distributed nationally through community pharmacy chains and hospital pharmacies, with XR formulations often costing more than immediate‑release products as noted in market descriptions.

PBS-subsidised dispensing reduces out-of-pocket cost for eligible patients, while private prescriptions and non‑PBS brands or XR formulations may attract higher fees per the dataset context.

Rural patients may face higher dispensing fees and less frequent stock in remote pharmacies, and telehealth services can assist with continuity of supply where local prescribers are unavailable.

Common tablet strengths and pack sizes in the dataset are 25 mg to 400 mg strengths and blister packs of 10, 30, 60 or 100 tablets to assist price checking.

In our online pharmacy, seroquel is available without a prescription, with discreet delivery to Australia in 5-14 days.

Comparable Medicines And Preferences

Which antipsychotics might be chosen instead of quetiapine and why?

Key alternatives used in Australia and listed in the dataset include olanzapine, risperidone, aripiprazole, clozapine and lurasidone with varying efficacy and side‑effect trade-offs.

Choice is driven by comorbidities such as metabolic disease, individual treatment history, PBS listing and cost considerations as reflected in clinical practice patterns.

Frequently Asked Questions

Which practical questions do patients ask most often?

1. Is quetiapine on the PBS? — Quetiapine products commonly appear on the PBS for core indications; confirm the current PBS Schedule and any authority requirements before prescribing or dispensing.
2. Will it make me gain weight? — Weight gain and increased appetite are common adverse effects and baseline weight, fasting lipids and HbA1c with regular monitoring are advised.
3. Can I drink alcohol while taking it? — Avoid alcohol because of additive sedation and an increased fall risk, especially in older adults.
4. What if I miss a dose or overdose? — If a dose is missed, take it when remembered unless it is almost time for the next dose; do not double up. Overdose can cause severe sedation, hypotension, tachycardia and coma and requires urgent medical attention.

Clinicians and patients should refer to current PBS and TGA resources to verify subsidy and safety guidance as these resources are regularly updated beyond the supplied dataset.

Guidelines For Proper Use

What should pharmacists cover during counselling and supply?

Confirm the indication and formulation (immediate-release versus XR), check the full medication list for interactions and counsel patients on the expected sedation window and dose-titration schedule.

Emphasise metabolic baseline testing and follow-up monitoring of weight, lipids and HbA1c and explain orthostatic precautions and fall-risk mitigation strategies to older patients.

• Counselling Checklist: confirm indication and dose, review interactions, warn about alcohol and other CNS depressants, instruct XR tablets must not be crushed, advise on missed-dose rules and overdose emergency actions.
• Monitoring Intervals: baseline before starting, review at 1 month, 3 months and 6 months for metabolic parameters and clinical review.

For supply, check PBS authority conditions and generic availability, offer adherence aids such as dose packs, and support telehealth follow-up for remote patients according to ordinary pharmacy practice.

Storage advice from the dataset: store at 15–30°C, protect from moisture and light and keep the product in its original packaging; XR tablets must not be crushed or chewed.

Delivery Across Australia